Skip to main content
Close
Home
Society of Hospital Medicine
Presented by Society of Hospital Medicine
Home
Twitter Facebook LinkedIn Instagram YouTube Hospital Medicine Exchange Email RSS Feed

Richard Mark Kirkner

News

Sleep disorders and cancer: It’s complicated

Author:
Richard Mark Kirkner
Publish date: December 6, 2021

Sleep apnea and other sleep disorders appear to elevate the risk for some types of cancer, but lower the risk in...

  • Read More

News

Low-dose rituximab may keep RA disease activity low in responders

Author:
Richard Mark Kirkner
Publish date: November 19, 2021

Rituximab doses as low as 200 mg were effective in treating rheumatoid arthritis, an extension study of a small trial in the Netherlands found.

  • Read More

News

Tofacitinib postmarketing trial data shed light on JAK inhibitor risks

Author:
Richard Mark Kirkner
Publish date: November 16, 2021

Analyses of the phase 3b/4 ORAL Surveillance trial results found independent factors for risk for major adverse cardiovascular events, cancer, and...

  • Read More

News

For EGPA vasculitis, rituximab comparable with cyclophosphamide for inducing remission

Author:
Richard Mark Kirkner
Publish date: November 15, 2021

A phase 3 trial has found that rituximab is not superior to cyclophosphamide to induce remission in eosinophilic granulomatosis with polyangiitis...

  • Read More

News

mRNA COVID vaccine response found mostly robust in RA, SLE patients

Author:
Richard Mark Kirkner
Publish date: November 11, 2021

A trial found that immunosuppressed adults with autoimmune disease had a robust antibody response to the mRNA vaccine with no excess adverse...

  • Read More

News

Statins’ effects on CVD outweigh risk for diabetes in RA

Author:
Richard Mark Kirkner
Publish date: November 9, 2021

A large cohort study reports that the cardiovascular benefits of statin use in people with rheumatoid arthritis outweigh the moderate diabetes...

  • Read More

News

Abatacept shows signal to delay onset of rheumatoid arthritis

Author:
Richard Mark Kirkner
Publish date: November 8, 2021

Early results of a randomized clinical trial show that a 6-month course of abatacept may delay or prevent progression to rheumatoid arthritis.

  • Read More

News

AHA: Quality of STEMI care has stalled, needs improvement

Author:
Richard Mark Kirkner
Publish date: October 19, 2021

A new American Heart Association policy statement recommends actions to improve care for people who have ST-segment elevation MI.

  • Read More

News

Study identifies pandemic-related stressor in Parkinson’s disease

Author:
Richard Mark Kirkner
Publish date: September 23, 2021

Researchers in the Netherlands identified COVID-19–related stressors for people with Parkinson’s disease and the most vulnerable subgroups.

  • Read More

News

Investigative botulinum toxin formulation shows prolonged effect

Author:
Richard Mark Kirkner
Publish date: September 23, 2021

A phase 3 trial reported that a new formulation of a botulinum toxin had a longer duration of effect with fewer side effects than existing...

  • Read More

News

Efforts target underrepresented populations in Parkinson’s disease genetic studies

Author:
Richard Mark Kirkner
Publish date: September 23, 2021

Genetic studies in Parkinson’s disease have been heavily skewed to European populations, but a number of efforts aim to make study populations...

  • Read More

News

Synthetic triglyceride shows potential in Huntington’s disease

Author:
Richard Mark Kirkner
Publish date: September 23, 2021

An extension study found that the synthetic medium-chain triglyceride triheptanoin improved brain energy and caudate atrophy in Huntington’s...

  • Read More

News

RA treatment responders show unique differences in gut microbiome

Author:
Richard Mark Kirkner
Publish date: September 22, 2021

A cohort study found differences in the gut microbiome between patients with rheumatoid arthritis who improved clinically and those who did not....

  • Read More

News

Friedreich’s ataxia treatment shows extended benefit

Author:
Richard Mark Kirkner
Publish date: September 21, 2021

An extension study of the Nrf2 activator omaveloxolone in people with Friedreich’s ataxia showed benefit out to more than 2 years.

  • Read More

News

Survey identifies clinicians’ unease with genetic testing

Author:
Richard Mark Kirkner
Publish date: September 21, 2021

A survey of Movement Disorders Society members identified a number of gaps in clinicians’ comfort levels with genetic testing for Parkinson’s...

  • Read More

Pages

  • « first
  • …
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • last »
An Official Publication of the Society of Hospital Medicine

Society of Hospital Medicine
Twitter Facebook LinkedIn Instagram YouTube Hospital Medicine Exchange Email RSS Feed

Copyright  © 2023 Frontline Medical Communications Inc., Newark, NJ, USA. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

Menu Close